ALLMedicine™ Hypereosinophilic Syndrome Center

Nov 5th, 2021 - Definition The term myocarditis refers to an inflammatory response within the myocardium that is not secondary to ischemic events or cardiac rejection in the setting of transplantation. The presence of myocyte necrosis is required for certain type...

Oct 3rd, 2021 - Eosinophilia can occur due to a plethora of allergic, infective, neoplastic and idiopathic conditions. Hypereosinophilic syndrome (HES) is characterised by sustained eosinophilia and multiorgan dysfunction in the absence of an identifiable cause. ...

Sep 20th, 2021 - The purpose of this program is to allow access to nilotinib for eligible patients diagnosed with Hypereosinophilic syndrome (HES). The patient's Treating Physician should follow the suggested treatment guidelines and comply with all local health a...

Sep 14th, 2021 - Hypereosinophilic syndrome (HES) is a rare group of heterogeneous disorders characterized by marked peripheral eosinophilia (>1500/(micro)L) and evidence of eosinophil-associated tissue damage. Although a high proportion of patients respond initia...

Aug 23rd, 2021 - Idiopathic hypereosinophilic syndrome with cardiac involvement is characterized by endocardial fibrosis and thrombosis. Here, we report a case of mitral valve prosthetic dysfunction in a patient with idiopathic hypereosinophilic syndrome and revie...

Sep 20th, 2021 - The purpose of this program is to allow access to nilotinib for eligible patients diagnosed with Hypereosinophilic syndrome (HES). The patient's Treating Physician should follow the suggested treatment guidelines and comply with all local health a...

Sep 14th, 2021 - Hypereosinophilic syndrome (HES) is a rare group of heterogeneous disorders characterized by marked peripheral eosinophilia (>1500/(micro)L) and evidence of eosinophil-associated tissue damage. Although a high proportion of patients respond initia...

Sep 4th, 2020 - Introduction: The etiology and therapy of eosinophilic lung diseases are still poorly understood. For individual forms of disease, such as eosinophilic asthma or eosinophilic granulomatosis with polyangiitis (EGPA), new therapeutic approaches exis...

Aug 26th, 2020 - There is currently no data on the natural history of unexplained chronic hypereosinophilia (HE) and hypereosinophilic syndromes (HES). Clinical practice shows that HE/SHE patients can present 4 evolutionary profiles: A. a single flare-up of their ...

Feb 15th, 2019 - The purpose is to characterize new hypereosinophilic syndrome biomarkers more informative and more accessible compared to those that we have already thanks to a proteomic approach. This will help the investigators to diagnose the this disease.

May 25th, 2021 - Dysregulated platelet-derived growth factor receptor (PDGFR) signaling is implicated in a number of cancer types and is among the targets of many FDA-approved multikinase inhibitors.1,2 Despite the success of these drugs in a range of malignancies...

Oct 2nd, 2020 - Seven former FDA commissioners from both parties penned an editorial criticizing the Trump administration for suggesting it could influence scientific standards for vaccine approval, potentially undermining public confidence in the agency's decisi...

Sep 28th, 2020 - The US Food and Drug Administration (FDA) has expanded the indication for mepolizumab (Nucala, GlaxoSmithKline) to include patients with hypereosinophilic syndrome (HES). Mepolizumab is indicated for adults and children aged 12 years and older wit...

Sep 28th, 2020 - The US Food and Drug Administration (FDA) has expanded the indication for mepolizumab (Nucala, GlaxoSmithKline) to include patients with hypereosinophilic syndrome (HES). Mepolizumab is indicated for adults and children aged 12 years and older wit...

Sep 18th, 2017 - Photo by Patrick Pelletier Imatinib tablet cut with a pill splitter The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended granting marketing authorization for Imatinib Teva B. V.